An intensive care unit team evaluates a 62-year-old man who complains of sudden, intense p… — USMLE Step 3

An intensive care unit team evaluates a $62$ -year-old man who complains of sudden, intense pain and swelling in his left lower extremity. He was admitted $6$ days prior for a massive right-sided pulmonary embolism and has been receiving a continuous intravenous unfractionated heparin infusion since admission. His medical history is significant for hypertension, type 2 diabetes mellitus, and end-stage renal disease requiring hemodialysis three times weekly.

Temperature is $37.1^\circ\text{C}$ ( $98.8^\circ\text{F}$ ), blood pressure is $135/85\text{ mm Hg}$ , pulse is $98/\text{min}$ , and respirations are $18/\text{min}$ . Physical examination shows a remarkably swollen, erythematous, and tender left lower extremity extending from the calf to the mid-thigh. Peripheral pulses are palpable bilaterally.

Laboratory studies obtained today (Hospital Day $6$ ) compared to admission (Hospital Day $1$ ) are as follows:

Laboratory Parameter	Hospital Day 1	Hospital Day 6
Platelet count	$240,000/\text{mm}^3$	$95,000/\text{mm}^3$
Serum creatinine	$5.8\text{ mg/dL}$	$6.1\text{ mg/dL}$

A duplex ultrasonography of the left lower extremity demonstrates a new acute deep vein thrombosis in the left femoral and popliteal veins. Unfractionated heparin is immediately discontinued.

Which of the following is the most appropriate next step in pharmacologic management?

Initiate intravenous argatrobanAnswer
B
Initiate subcutaneous fondaparinux
C
Initiate subcutaneous enoxaparin
D
Initiate oral warfarin
E
Transfuse pooled platelets

Answer

Initiate intravenous argatroban

The correct intervention is to initiate intravenous argatroban. This patient has developed heparin-induced thrombocytopenia (HIT) complicated by a new deep vein thrombosis, an immunologic reaction mediated by antibodies against the heparin-platelet factor 4 (PF4) complex. The diagnostic criteria include a platelet drop of

>50\%

, typical timing of

5

10

days after heparin exposure, new thrombosis, and the absence of other obvious causes. Management requires the immediate cessation of all heparin products and the urgent initiation of a non-heparin parenteral anticoagulant. Because this patient has end-stage renal disease, intravenous argatroban, a direct thrombin inhibitor that undergoes exclusive hepatic metabolism, is the anticoagulant of choice.

Step-by-Step Solution

Identify the primary complication occurring on hospital day 6.

The patient developed a

>50\%

drop in platelet count (from

240,000/\text{mm}^3

95,000/\text{mm}^3

) alongside a new venous thrombosis.

Recognizing the timeline and presentation meets the classic clinical criteria (the 4T's) for heparin-induced thrombocytopenia (HIT).

Determine the immediate necessary intervention for HIT.

All unfractionated heparin was appropriately discontinued, and the next step is starting an alternative non-heparin parenteral anticoagulant.

HIT is a highly prothrombotic state; stopping heparin alone is insufficient to prevent devastating thrombotic complications like limb gangrene or recurrent pulmonary embolism.

Select the appropriate non-heparin anticoagulant based on the patient's specific comorbidities.

Argatroban is chosen over fondaparinux, enoxaparin, or bivalirudin.

The patient has end-stage renal disease (creatinine

> 6.0\text{ mg/dL}

). Argatroban undergoes exclusive hepatic clearance, whereas fondaparinux is renally cleared and absolutely contraindicated.

Key Concept

Management of Heparin-Induced Thrombocytopenia (HIT) in End-Stage Renal Disease

Estimated Time:1m 30s

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic